Home › Companies › Oruka Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Oruka Therapeutics, Inc.’s Form 8-K, filed 2026-06-04 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2025-2026
Explore Oruka Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Oruka Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Lawrence Klein | 43,918,579 | -- | -- | 63,593 | -- | Majority: yes |
| Elect Director: Chris Martin | 43,936,173 | -- | -- | 45,999 | -- | Majority: yes |
| Proposal 2: Ratification of Independent Auditor Appointment | 45,206,297 | 39,637 | 3,432 | -- | -- | Majority: yes |
| Proposal 3: Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis | 43,033,967 | 875,114 | 73,091 | -- | -- | Majority: yes |
Source: Oruka Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-04 — read the filing on EDGAR.
Each item below shows how the 211 asset managers that disclosed a Oruka Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Oruka Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 9 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Oruka Therapeutics, Inc.’s own tally for this item (“Proposal 3: Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis”): 43,033,967 for, 875,114 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 50,167,623 outstanding shares: 86% for, 2% against (88% of the company cast a for/against vote).
The 208 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 14,343,671 | 0 | 0 | 0 | For |
| Venrock Adviser, LLC | 4,180,907 | 0 | 0 | 0 | For |
| Fairmount Funds Management LLC | 3,705,262 | 0 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 2,666,690 | 0 | 0 | 0 | For |
| Vanguard | 2,486,826 | 1 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 2,052,606 | 0 | 0 | 0 | For |
| BlackRock | 2,030,771 | 14,795 | 0 | 0 | For |
| Deep Track Capital, LP | 2,019,203 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 1,981,696 | 0 | 0 | 0 | For |
| Remedium Capital Partners, LLC | 1,565,661 | 0 | 0 | 0 | For |
| State Street | 1,307,472 | 4,713 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 1,076,829 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 931,358 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 914,296 | 0 | 0 | 0 | For |
| T. Rowe Price | 791,116 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 760,424 | 0 | 0 | 0 | For |
| Charles Schwab | 644,209 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 479,028 | 0 | 0 | 0 | For |
| SR ONE CAPITAL MANAGEMENT, LP | 430,330 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 411,006 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 405,297 | 0 | 0 | 0 | For |
| Holocene Advisors, LP | 376,154 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 370,590 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 366,660 | 0 | 0 | 0 | For |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 258,427 | 2,233 | 0 | 0 | For |
Showing the 25 largest of 208 asset managers. See all 208 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Oruka Therapeutics, Inc.’s own tally for this item (“Proposal 2: Ratification of Independent Auditor Appointment”): 45,206,297 for, 39,637 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 50,167,623 outstanding shares: 90% for, 0.1% against (90% of the company cast a for/against vote).
The 58 asset managers below cast 100% of the shares they voted on this item FOR (14,548,642 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,975,958 | 0 | 0 | 0 | For |
| Vanguard | 2,187,100 | 0 | 0 | 0 | For |
| Remedium Capital Partners, LLC | 1,565,661 | 0 | 0 | 0 | For |
| BlackRock | 1,157,726 | 0 | 0 | 0 | For |
| State Street | 709,423 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 405,297 | 0 | 0 | 0 | For |
| Charles Schwab | 322,103 | 0 | 0 | 0 | For |
| T. Rowe Price | 308,828 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 140,840 | 0 | 0 | 0 | For |
| Equitable | 95,132 | 0 | 0 | 0 | For |
| TIAA | 82,962 | 0 | 0 | 0 | For |
| American Century | 74,067 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,957 | 0 | 0 | 0 | For |
| JPMorgan | 52,598 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 33,055 | 0 | 0 | 0 | For |
| Russell Investments | 31,780 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 29,318 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 27,000 | 0 | 0 | 0 | For |
| Voya | 24,453 | 0 | 0 | 0 | For |
| Brighthouse | 23,691 | 0 | 0 | 0 | For |
| John Hancock | 19,620 | 0 | 0 | 0 | For |
| Global X | 18,017 | 0 | 0 | 0 | For |
| Northern Trust | 17,896 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 17,543 | 0 | 0 | 0 | For |
| Pacific Life | 15,026 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.
Combines 5 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Oruka Therapeutics, Inc.’s own tally for this item (“Elect Director: Chris Martin”): 43,936,173 for, 45,999 withheld, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 50,167,623 outstanding shares: 88% for, 0.1% withheld (88% of the company cast a for/withheld vote).
The 55 asset managers below cast 100% of the shares they voted on this item FOR (14,520,843 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,975,958 | 0 | 0 | 0 | For |
| Vanguard | 2,187,100 | 0 | 0 | 0 | For |
| Remedium Capital Partners, LLC | 1,565,661 | 0 | 0 | 0 | For |
| BlackRock | 1,157,726 | 0 | 0 | 0 | For |
| State Street | 709,423 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 405,297 | 0 | 0 | 0 | For |
| Charles Schwab | 322,103 | 0 | 0 | 0 | For |
| T. Rowe Price | 308,828 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 140,840 | 0 | 0 | 0 | For |
| Equitable | 95,132 | 0 | 0 | 0 | For |
| TIAA | 82,962 | 0 | 0 | 0 | For |
| American Century | 74,067 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,957 | 0 | 0 | 0 | For |
| JPMorgan | 52,598 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 33,055 | 0 | 0 | 0 | For |
| Russell Investments | 31,780 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 29,318 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 27,000 | 0 | 0 | 0 | For |
| Voya | 24,453 | 0 | 0 | 0 | For |
| Brighthouse | 23,691 | 0 | 0 | 0 | For |
| John Hancock | 19,620 | 0 | 0 | 0 | For |
| Global X | 18,017 | 0 | 0 | 0 | For |
| Northern Trust | 17,896 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 17,543 | 0 | 0 | 0 | For |
| Pacific Life | 15,026 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.
Combines 5 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Oruka Therapeutics, Inc.’s own tally for this item (“Elect Director: Lawrence Klein”): 43,918,579 for, 63,593 withheld, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 50,167,623 outstanding shares: 88% for, 0.2% withheld (88% of the company cast a for/withheld vote).
The 55 asset managers below cast 100% of the shares they voted on this item FOR (14,517,711 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,975,958 | 0 | 0 | 0 | For |
| Vanguard | 2,187,100 | 0 | 0 | 0 | For |
| Remedium Capital Partners, LLC | 1,565,661 | 0 | 0 | 0 | For |
| BlackRock | 1,157,726 | 0 | 0 | 0 | For |
| State Street | 709,423 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 405,297 | 0 | 0 | 0 | For |
| Charles Schwab | 322,103 | 0 | 0 | 0 | For |
| T. Rowe Price | 308,828 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 140,840 | 0 | 0 | 0 | For |
| Equitable | 95,132 | 0 | 0 | 0 | For |
| TIAA | 82,962 | 0 | 0 | 0 | For |
| American Century | 74,067 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,957 | 0 | 0 | 0 | For |
| JPMorgan | 52,598 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 33,055 | 0 | 0 | 0 | For |
| Russell Investments | 31,780 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 29,318 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 27,000 | 0 | 0 | 0 | For |
| Voya | 24,453 | 0 | 0 | 0 | For |
| Brighthouse | 23,691 | 0 | 0 | 0 | For |
| John Hancock | 19,620 | 0 | 0 | 0 | For |
| Global X | 18,017 | 0 | 0 | 0 | For |
| Northern Trust | 17,896 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 17,543 | 0 | 0 | 0 | For |
| Pacific Life | 15,026 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.
All nominees (reported as one line). These filers reported the election of directors as a single line covering every nominee. It is not attributed to any one director, and no share total is shown for it.
100% fund support · no official result
The 3 asset managers below cast 100% of the shares they voted on this item FOR.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Tactical Investment Series Trust | 12,065 | 0 | 0 | 0 | For |
| Franklin Alternative Strategies Funds | 7,867 | 0 | 0 | 0 | For |
| Putnam | 7,867 | 0 | 0 | 0 | For |
98% Majority: yes · of votes cast
Oruka Therapeutics, Inc.’s own tally for this item (“Proposal 3: Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis”): 43,033,967 for, 875,114 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 50,167,623 outstanding shares: 86% for, 2% against (88% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (437 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Empower | 437 | 0 | 0 | 0 | For |
| Ikarian Capital, LLC | 0 | 0 | 0 | 0 | -- |
Ranked by the number of Oruka Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 50,167,623 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 28.59% |
| 2 | Venrock Adviser, LLC | 8.33% |
| 3 | Fairmount Funds Management LLC | 7.39% |
| 4 | VIKING GLOBAL INVESTORS LP | 5.32% |
| 5 | Vanguard | 4.96% |
| 6 | RTW INVESTMENTS, LP | 4.09% |
| 7 | BlackRock | 4.08% |
| 8 | Deep Track Capital, LP | 4.02% |
| 9 | Polar Capital Holdings Plc | 3.95% |
| 10 | Remedium Capital Partners, LLC | 3.12% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Fairmount Funds Management LLC | 29.01% | 13D |
| Entities affiliated with Fairmount Funds Management LLC | 22.25% | DEF14A |
| Peter Harwin | 22.25% | DEF14A |
| FMR (Fidelity) | 14.81% | 13F |
| FMR LLC | 14.47% | DEF14A |
| Entities affiliated with Venrock Healthcare Capital Partners | 9.79% | DEF14A |
| Venrock Healthcare Capital Partners III, L.P. | 9.08% | 13G |
| BlackRock | 7.03% | 13F |
| Capital World Investors | 6.78% | 13G |
| Entities affiliated with BlackRock, Inc. | 6.33% | DEF14A |
Percentages above are of 50,167,623 shares outstanding, as reported by Oruka Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Oruka Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Oruka Therapeutics, Inc.'s shareholder meeting held 2026-06-02, in the 2025-2026 proxy season, 211 asset managers reported how they voted in their SEC Form N-PX filings, covering 899 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executive officers. — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Oruka Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-04.
Oruka Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).